Using the GEPIA2 database and the TCGA pan-cancer cohort, our analysis showed that high TLCD1 mRNA expression levels were significantly associated with decreased OS in patients with ACC (HR = 3.1), GBM (HR = 2.2), KIRC (HR = 2.2), LIHC (HR = 1.7), OV(HR = 0.75), THYM (HR = 8.6) and UVM (HR = 4.6), however, in OV (HR = 0.75) patients, low TLCD1 mRNA expression levels were significantly associated with OS decline (Figures 4B–I). This evidence concerns the gene TLCD1 and adrenal cortex carcinoma.